<DOC>
	<DOCNO>NCT00310336</DOCNO>
	<brief_summary>50-60 % patient chronic hepatitis C cure treatment pegylated IFNα plus ribavirin . Retreatment non-responders previous ( pegylated ) IFNα plus ribavirin therapy pegylated IFNα plus ribavirin result sustain response le 10 % patient . Extensive analysis IFNα signal cell express HCV protein , transgenic mouse express HCV protein , liver biopsy patient chronic hepatitis C point STAT1 methylation important posttranslational modification target HCV inhibit IFNα signaling . STAT1 methylation increase IFNα improve add AdoMet betaine . The study design test hypothesis combination treatment pegylated IFNα2b , ribavirin , AdoMet betaine superior current standard combination therapy pegylated IFNα plus ribavirin .</brief_summary>
	<brief_title>Chronic Hepatitis C Non-Responder Study With AdoMet Betaine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Betaine</mesh_term>
	<criteria>Male female 18 65 year . Nonresponders previous treatment IFNα plus ribavirin pegylated IFNα plus ribavirin . Elevated ALTlevels least two occasion &gt; 6 month precede entry . Detection HCV RNA serum ( PCR ) . Compensated liver disease ( ChildPugh A ) ChildPugh score &lt; 5 . The follow minimal hematologic biochemical criterion : Hemoglobin male females &gt; 11g/dl Absolute Neutrophil count &gt; 1500 cells/mm3 Platelets &gt; 75'000/mm3 HBs Ag negative . ANA &lt; 1:320 , evidence autoimmune hepatitis . αFetoprotein &lt; 50μg/l ( upper limit normal 50μg/l , ultrasonographical exclusion hepatocellular carcinoma ( HCC ) need ) . Fasting blood glucose within normal limit , history diabetes hypertension , pretherapy ocular examination indicate . TSH within normal limit adequately control . Negative urine blood pregnancy test ( woman childbearing potential ) document within 23 week period prior first dose study drug . Additionally , fertile male female must use effective contraception treatment 6 month treatment end . This may include , limited , use birth control pill , IUDs , condom , diaphragm , implant , surgically sterilize , postmenopausal state . Willingness give write informed consent willingness participate comply study Women ongoing pregnancy breast feeding . Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , HBe Ag . Positive test screen HIV . History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) . Hypersensitivity study drug . Participation clinical trial within 30 day entry protocol . Treatment investigational drug within 30 day entry protocol . History evidence decompensated liver disease ( ChildPugh B/C ) ChildPugh score &gt; 5 . Ascites , coagulopathy , hyperbilirubinemia , hepatic encephalopathy , hypoalbuminemia ChildPugh score &gt; 5 condition consistent decompensated liver disease . History evidence bleed esophageal varix condition consistent decompensated liver disease . Hepatocellular carcinoma ( HCC ) αFetoprotein &gt; 50μg/l . Patients organ transplant cornea hair transplant . Therapy antisystemic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; 6 month prior first dose study drug Hemoglobinopathy ( e.g . thalassemia ) cause tendency hemolysis . Any known preexisting medical condition could interfere patient 's participation completion study : Preexisting psychiatric condition , especially depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt ( base mandatory psychiatric advice ) . CNS trauma active seizure disorder require medication . Significant cardiovascular dysfunction . Poorly control diabetes mellitus . Renal dysfunction , i.e . serum creatinine level &gt; 1.5 time upper limit normal . Autoimmune diseases . Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration ) . Any medical condition requiring , likely require course study , chronic systemic administration steroid . Clinical gout . Important substance abuse ( alcohol &gt; 80 g/d , i.v . drug etc. ) . Active opportunistic infection . NonHodgkin lymphoma Hodgkin lymphoma . Kaposi sarcoma . Inability unwillingness provide inform consent abide requirement study . Male partner pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>